Peter Westervelt

Hematology | Oncology

329 Maine St Ste E101
Brunswick, ME 04011

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 140 publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Journal: The New England journal of medicine

Published: September 02, 2026

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.

Journal: NEJM evidence

Published: August 25, 2026

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Journal: Blood advances

Published: March 09, 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Journal: Blood advances

Published: March 09, 2026

Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.

Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.

Journal: Blood advances

Published: January 07, 2026

Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.

Antigen-specific T cell responses to SARS-CoV-2 vaccination after Hematopoietic Cell Transplant or CAR T cell Therapy.

Journal: Blood advances

Published: January 07, 2026

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy

Published: December 04, 2025

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 18, 2025

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy

Published: September 03, 2025

Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation.

Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: July 08, 2025

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.

Journal: medRxiv : the preprint server for health sciences

Published: October 07, 2024

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation.

Journal: Blood

Published: August 08, 2024

Showing 1-12 of 140

Last Updated: 09/26/2026